<DOC>
	<DOCNO>NCT00814879</DOCNO>
	<brief_summary>This pilot study provide data safety efficacy combination Raltegravir ( RAL ) 400mg BID + Atazanavir ( ATV ) 300 mg BID Antiretroviral ( ARV ) -experienced subject suppress HIV viral load Ritonavir ( RTV ) boost Protease Inhibitor ( PI ) base regimen switch regimen RAL 400mg BID +ATV 300mg BID .</brief_summary>
	<brief_title>Pilot Study Raltegravir Based NRTI Sparing Regimen</brief_title>
	<detailed_description>The purpose pilot study compare virological efficacy , measure proportion patient plasma HIV-RNA limit detection ( &lt; 50 copies/mL ) , two ARV regimen ; patient randomize remain regimen contain N ( ) RTI ( ) + PI/r switch Raltegravir + ATV without N ( ) RTI ( ) . Study Arms : 1 . N ( ) RTI ( ) base backbone + PI/r 2 . Raltegravir ( RAL ) 400mg BID + atazanavir ( ATV ) 300 mg BID Antiretroviral ( ARV ) treatment guideline currently recommend ARV regimens contain Nucleos ( ) ide Reverse Transcriptase Inhibitors [ N ( ) RTI ( ) ] base backbone Non Nucleoside Reverse Transcriptase Inhibitor ( NNRTI ) ritonavir boost Protease Inhibitor ( PI/r ) . ( 1 ) However , significant toxicity associate N ( ) RTI ( ) PI/r contain regimen . N ( ) RTI ( ) cause lipoatrophy , lipid elevation , renal toxicity , neuropathy lactic acidosis . ( 1 ) These toxicity require clinician HIV-infected individual use alternative ARV regimen use N ( ) RTI ( ) . PIs know cause gastrointestinal side effect , dyslipidemia , fat maldistribution ( lipodystrophy ) . ( 1 ) The DHHS HIV treatment guideline recommend PIs give low dose ritonavir ( RTV ) . RTV PI inhibitory effect cytochrome P-450 3A4 isoenzyme metabolizes PIs . The addition RTV serve pharmacokinetic `` booster '' increase PI drug concentration . ( 1 ) However , RTV know increase PI side effect , elevate lipid level significant drug-drug interaction many medication give HIV+ individual . ( 1 ) These RTV drug interaction complicate medical care HIV-infected individual . Raltegravir ( RAL ) recently FDA approve antiretroviral agent inhibits HIV replication block integration HIV proviral DNA host cell chromosomal DNA . RAL exhibit cross resistance ARV class thus initially use HIV-infected individual infect drug resistant HIV strain . Recently publish data use RAL ( 2,3 ) HIV-infected subject know ARV drug resistance without ARV drug resistance4 demonstrate RAL potent agent , suppress HIV viral load majority subject excellent CD4 cell response . ( 2-4 ) RAL metabolize glucuronidation uridine diphosphate-glucuronosyl transferase 1A1 ( UGT1A1 ) enzyme pathway . ( 5 ) ATV know inhibitor enzyme pathway . ATV increase RAL level , ( 5 ) however , current DHHS HIV treatment guideline recommend change dose RAL give ATV person receive ATV RAL demonstrate good tolerability combination low side effect profile . ( 1-3,5 ) The availability RAL provide opportunity examine alternative ARV strategy may equally efficacious less toxic currently recommend HIV treatment guideline . Such combination might include RAL+ATV regimen without concomitant N ( ) RTI ( ) base backbone and/or inclusion RTV . However , little data available date regard combination . HIV care provider already begin use combination RAL+ unboosted ATV patient care intolerant RTV major side effects/toxicity N ( ) NRTIs . More investigation require determine RAL+ATV efficacious safe alternative RTV boost PI base ARV strategy . Before RAL base strategy include N ( ) RTIs RTV compare ARV class strategy long-term efficacy outcome , preliminary data RAL+ATV base regimen need . This pilot study provide data safety efficacy combination RAL 400mg BID + ATV 300 mg BID ARV-experienced subject suppress HIV viral load RTV boost PI base regimen switch regimen RAL 400mg BID +ATV 300mg BID .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV1 positive On stable ARVtherapy minimum 4 month HIV viral load &lt; 50 copy Currently N ( ) RTI ( ) base backbone + PI/r No prior history PI drug resistance ( historical genotype phenotype ) Aged &gt; 18 year age Written inform consent Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 8 week last dose investigational product , manner risk pregnancy minimize . Prior exposure Raltegravir Elvitegravir A detectable HIV viral load &gt; 50 copy within last 4 month An ARV change within last 4 month History PI drug resistance Prior virologic failure ATV contain regimen Prior history intolerance ATV Pregnant nursing mother Preexisting grade 3 laboratory toxicity except lipid : Absolute neutrophil count ( ANC ) &lt; 750 cells/mL . Hemoglobin &lt; 8.0 g/dL . Platelet count &lt; 50 000 cells/mL . AST , ALT alkaline phosphatase &gt; 5 x ULN . Serum bilirubin &gt; 5 x ULN . calculate creatinine clearance &lt; 50mL/min/1.73m2 Patients chronic active hepatitis B infection define positive serum Hbs antigen Use prohibit medication and/or use proton pump inhibitor ATV plus RAL contain regimen ) Patients current alcohol illicit substance use judgment investigator make study adherence unlikely</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Acquired Immune Deficiency Syndrome</keyword>
	<keyword>AIDS</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Antiretroviral</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>NRTI</keyword>
	<keyword>Nucleoside Reverse Transcriptase Inhibitors</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Resistance</keyword>
	<keyword>treatment experience</keyword>
</DOC>